JP2019536767A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019536767A5 JP2019536767A5 JP2019523821A JP2019523821A JP2019536767A5 JP 2019536767 A5 JP2019536767 A5 JP 2019536767A5 JP 2019523821 A JP2019523821 A JP 2019523821A JP 2019523821 A JP2019523821 A JP 2019523821A JP 2019536767 A5 JP2019536767 A5 JP 2019536767A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitors
- inhibitor
- epicatechin
- compounds
- kinase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 14
- 239000003112 inhibitor Substances 0.000 claims 14
- PFTAWBLQPZVEMU-ZFWWWQNUSA-N (+)-epicatechin Natural products C1([C@@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-ZFWWWQNUSA-N 0.000 claims 9
- PFTAWBLQPZVEMU-UKRRQHHQSA-N (-)-epicatechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-UKRRQHHQSA-N 0.000 claims 6
- 230000001093 anti-cancer Effects 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- -1 nitoseurea Chemical compound 0.000 claims 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 4
- PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-3',4',5,7-Tetrahydroxy-2,3-trans-flavan-3-ol Natural products C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 claims 3
- 235000007246 (+)-epicatechin Nutrition 0.000 claims 3
- 235000007355 (-)-epicatechin Nutrition 0.000 claims 3
- 229930013783 (-)-epicatechin Natural products 0.000 claims 3
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 claims 3
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 claims 3
- 235000012734 epicatechin Nutrition 0.000 claims 3
- LPTRNLNOHUVQMS-UHFFFAOYSA-N epicatechin Natural products Cc1cc(O)cc2OC(C(O)Cc12)c1ccc(O)c(O)c1 LPTRNLNOHUVQMS-UHFFFAOYSA-N 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 2
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 229960002949 fluorouracil Drugs 0.000 claims 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- 229940124302 mTOR inhibitor Drugs 0.000 claims 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 claims 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- HKTBGLYNZWOCKW-NSHDSACASA-N 4-[[4-(2-amino-1,3-thiazol-5-yl)-6-[(3s)-3-methylmorpholin-4-yl]-1,3,5-triazin-2-yl]oxy]-3-fluoro-n,n-dimethylbenzamide Chemical compound C[C@H]1COCCN1C1=NC(OC=2C(=CC(=CC=2)C(=O)N(C)C)F)=NC(C=2SC(N)=NC=2)=N1 HKTBGLYNZWOCKW-NSHDSACASA-N 0.000 claims 1
- BQPZIYSVGQSCET-UHFFFAOYSA-N 4-[[4-(2-amino-1,3-thiazol-5-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1OC1=NC(N2CCOCC2)=NC(C=2SC(N)=NC=2)=N1 BQPZIYSVGQSCET-UHFFFAOYSA-N 0.000 claims 1
- POAZEDQQRWSVGZ-ZDUSSCGKSA-N 4-[[4-(6-aminopyridin-3-yl)-6-[(3s)-3-methylmorpholin-4-yl]-1,3,5-triazin-2-yl]oxy]-3-fluoro-n,n-dimethylbenzamide Chemical compound C[C@H]1COCCN1C1=NC(OC=2C(=CC(=CC=2)C(=O)N(C)C)F)=NC(C=2C=NC(N)=CC=2)=N1 POAZEDQQRWSVGZ-ZDUSSCGKSA-N 0.000 claims 1
- BQRTZZXEYYXREE-UHFFFAOYSA-N 4-[[4-(6-aminopyridin-3-yl)-6-morpholin-4-yl-1,3,5-triazin-2-yl]oxy]-n,n-dimethylbenzamide Chemical compound C1=CC(C(=O)N(C)C)=CC=C1OC1=NC(N2CCOCC2)=NC(C=2C=NC(N)=CC=2)=N1 BQRTZZXEYYXREE-UHFFFAOYSA-N 0.000 claims 1
- 229940122531 Anaplastic lymphoma kinase inhibitor Drugs 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- 229940125431 BRAF inhibitor Drugs 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 claims 1
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- 102000043136 MAP kinase family Human genes 0.000 claims 1
- 108091054455 MAP kinase family Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 102100022596 Tyrosine-protein kinase ABL1 Human genes 0.000 claims 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 230000006682 Warburg effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000012635 anticancer drug combination Substances 0.000 claims 1
- 238000011319 anticancer therapy Methods 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 150000004663 bisphosphonates Chemical class 0.000 claims 1
- 230000000973 chemotherapeutic effect Effects 0.000 claims 1
- 229940046044 combinations of antineoplastic agent Drugs 0.000 claims 1
- 229960004397 cyclophosphamide Drugs 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 230000002414 glycolytic effect Effects 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 claims 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001024 immunotherapeutic effect Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 229960004768 irinotecan Drugs 0.000 claims 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims 1
- 229940043355 kinase inhibitor Drugs 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960001428 mercaptopurine Drugs 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 230000037361 pathway Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
- 239000003197 protein kinase B inhibitor Substances 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
- 229960000303 topotecan Drugs 0.000 claims 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
- JXLYSJRDGCGARV-CFWMRBGOSA-N vinblastine Chemical compound C([C@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-CFWMRBGOSA-N 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611037375 | 2016-11-01 | ||
| IN201611037375 | 2016-11-01 | ||
| PCT/IN2017/050506 WO2018083713A1 (en) | 2016-11-01 | 2017-11-01 | Composition comprising combination of epicatechin and anti-cancer compound |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019536767A JP2019536767A (ja) | 2019-12-19 |
| JP2019536767A5 true JP2019536767A5 (https=) | 2020-12-03 |
Family
ID=62076542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019523821A Pending JP2019536767A (ja) | 2016-11-01 | 2017-11-01 | エピカテキン及び抗癌化合物の組合せを含む組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20190262347A1 (https=) |
| EP (1) | EP3535252A4 (https=) |
| JP (1) | JP2019536767A (https=) |
| CN (1) | CN110312709A (https=) |
| WO (1) | WO2018083713A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012170430A1 (en) | 2011-06-06 | 2012-12-13 | Cardero Therapeutics, Inc. | Methods and compositions for treatment of mitochondrial toxicity |
| US20180193306A1 (en) | 2012-03-23 | 2018-07-12 | Cardero Therapeutics, Inc. | Compounds and compositions for the treatment of muscular disorders and bone disorders |
| CN106714770B (zh) | 2014-07-23 | 2024-04-19 | 斯法尔制药私人有限公司 | 羟基类固醇化合物、其中间体、制备方法、组合物及其用途 |
| EP3472176B1 (en) | 2016-06-21 | 2024-05-15 | Sphaera Pharma Pvt. Ltd. | Utility of (+) epicatechin and their analogs |
| BR112021007684A2 (pt) | 2018-10-24 | 2021-07-27 | Epirium Bio Inc. | cocristal, composição farmacêutica, métodos para tratar uma doença ou distúrbio que se beneficiaria da modificação da cadeia de transporte de elétrons, para reduzir os níveis de triglicerídeos, para tratar uma doença ou distúrbio selecionado a partir do grupo que consiste em uma síndrome metabólica, diabetes tipo ii, uma hiperlipidemia congênita e hiperlipidemia induzida por drogas, para tratar uma condição relacionada à disfunção mitocondrial, para melhorar o desempenho esportivo, resistência, construção de forma ou força muscular, ou facilitar a recuperação dos efeitos do treinamento ou competição e para tratar ou prevenir distrofinopatia, sarcoglicanopatia ou disferlinopatia, processo para preparar um cocristal, e, uso de um cocristal |
| JP6746022B1 (ja) * | 2020-02-13 | 2020-08-26 | シーシーアイホールディングス株式会社 | 腫瘍細胞におけるアスパラギン酸合成の阻害剤、腫瘍細胞のスフェロイド形成阻害剤、腫瘍細胞の転移抑制剤、解糖系阻害剤の作用増強剤、並びに腫瘍の転移の抑制および／または予防用医薬組成物 |
| CN115025236B (zh) * | 2022-05-09 | 2024-03-08 | 聊城大学 | 一种加载化疗药物-茶多酚联合药物的pH响应型靶向DNA纳米载药体系 |
| WO2024036225A1 (en) | 2022-08-10 | 2024-02-15 | Epirium Bio Inc. | Epicatechin for inhibiting glutamate toxicity |
| WO2024036223A1 (en) | 2022-08-10 | 2024-02-15 | Epirium Bio Inc. | Epicatechin inhibiting atp hydrolysis |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011105763A (ja) * | 2000-06-21 | 2011-06-02 | Kao Corp | Ｐｐａｒ依存的遺伝子転写活性化剤 |
| US7192612B2 (en) * | 2001-02-22 | 2007-03-20 | Purdue Research Foundation | Compositions and methods based on synergies between capsicum extracts and tea catechins for prevention and treatment of cancer |
| US20070054868A1 (en) * | 2005-06-20 | 2007-03-08 | The Trustees Of Columbia University In The City Of New York | Synergistic polyphenol compounds, compositions thereof, and uses thereof |
| WO2014016849A2 (en) * | 2012-07-23 | 2014-01-30 | Sphaera Pharma Pvt. Ltd. | Novel triazine compounds |
-
2017
- 2017-11-01 CN CN201780081834.1A patent/CN110312709A/zh active Pending
- 2017-11-01 EP EP17867283.8A patent/EP3535252A4/en not_active Withdrawn
- 2017-11-01 WO PCT/IN2017/050506 patent/WO2018083713A1/en not_active Ceased
- 2017-11-01 JP JP2019523821A patent/JP2019536767A/ja active Pending
- 2017-11-01 US US16/345,790 patent/US20190262347A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019536767A5 (https=) | ||
| Walker et al. | Beyond first-line chemotherapy for advanced pancreatic cancer: an expanding array of therapeutic options? | |
| JP2020504742A5 (https=) | ||
| Rodriguez et al. | Small cell lung cancer: past, present, and future | |
| DK2799070T3 (en) | EFFECTIVE AMPLIFIER FOR ANTITUMUM AGENTS | |
| US20200009144A1 (en) | Combination Therapy Comprising Varlitinib and an Anticancer Agent | |
| TWI798199B (zh) | 癌症治療 | |
| JP2013527232A5 (https=) | ||
| CN110312709A (zh) | 包含表儿茶素和抗癌化合物的组合的组合物 | |
| JP2008528468A5 (https=) | ||
| Melisi et al. | Pancreatic cancer: systemic combination therapies for a heterogeneous disease | |
| JP2023022190A (ja) | 癌治療 | |
| JP2021510725A5 (https=) | ||
| TW200803842A (en) | Antineoplastic combinations of temsirolimus and sunitinib malate | |
| WO2017184086A1 (en) | Method of treating liver cancer | |
| JP2019513812A5 (https=) | ||
| JP6978251B2 (ja) | がん治療 | |
| TWI837231B (zh) | 含有ｅｚｈ１／２雙重抑制劑之醫藥組合及其用途 | |
| JP2007531728A5 (https=) | ||
| JP2017532308A5 (https=) | ||
| JP2020520385A5 (https=) | ||
| RU2010140611A (ru) | Комбинированное применение производных холестанола | |
| WO2023202563A1 (en) | Akt inhibitor in combination with pim kinase inhibitor | |
| JP2018525413A5 (https=) | ||
| TWI650141B (zh) | 包含奎寧鹽懸浮液的用於抗癌治療的局部給藥用注射劑組合物 |